SCHEDULE: RTW Investments Boosts Orchestra Bio Holdings Stake

RTW Investments, LP and Roderick Wong, M.D. have filed an amendment to their Schedule 13D, reporting an increase in their beneficial ownership of Orchestra Biomed Holdings, Inc. common stock following a recent purchase.

Summary

• RTW Investments, LP and Roderick Wong, M.D. (collectively, the 'Reporting Persons') have filed Amendment No. 8 to their Schedule 13D regarding Orchestra Biomed Holdings, Inc.
• This amendment supplements the original filing from October 12, 2022, with updates on beneficial ownership.
• On November 9, 2026, the RTW Funds purchased 1,200,000 shares of common stock at $5.00 per share from the underwriters of the Issuer's public offering.
• These shares were funded by working capital of the RTW Funds.
• The Reporting Persons now beneficially own 13,142,394 shares, representing 16.2% of the outstanding common stock as of November 9, 2026.
• This percentage is calculated based on 78,704,957 shares outstanding, as reported in the Issuer's Form 10-Q filed on November 10, 2026, and includes Pre-Funded Warrants held by the RTW Funds.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a routine update on beneficial ownership and a recent stock purchase, without significant new strategic information or performance indicators.

Positives

• RTW Investments has increased its stake in Orchestra Biomed Holdings, Inc., indicating continued confidence in the company.
• The purchase of 1,200,000 shares at $5.00 per share was executed on November 9, 2026, during a public offering.
• The beneficial ownership now stands at 16.2% of the outstanding common stock, a significant holding.

Negatives

• The filing is an amendment to a previous filing, suggesting ongoing adjustments rather than a new strategic development.
• The previous settlement order with the SEC dated May 30, 2023, involved violations related to conflicts of interest disclosure and beneficial ownership reporting, including a $1.4 million civil penalty.

Risks

• The filing does not explicitly detail new risks but refers to the original statement, which would contain risk factors.
• The previous SEC settlement highlights potential past issues with disclosure and reporting compliance.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company. It primarily serves as an update to beneficial ownership reporting.

Management Comments

• "Unless otherwise defined herein, capitalized terms used in this Amendment No. 8 shall have the meanings ascribed to them in the Statement."
• "Unless amended or supplemented below, the information in the Statement remains unchanged."
• "All purchases of the securities described herein were for cash and were funded by working capital of the RTW Funds."
• "RTW Investments, LP By: /s/ Roderick Wong, M.D. Name: Roderick Wong, M.D. Title: Managing Partner"
• "Roderick Wong, M.D. /s/ Roderick Wong, M.D."

Industry Context

StockSavvy.ai notes that Schedule 13D filings are common for significant investors accumulating or adjusting their stakes in public companies. This filing indicates RTW Investments' continued active management of its portfolio in the biotechnology sector, a field often characterized by significant investment and potential volatility.

Legal Proceedings

• RTW Investments, LP entered into a settlement order with the SEC dated May 30, 2023 (File No. 3-21473).
• The SEC found violations of Sections 206(2) and 206(4) of the Investment Advisors Act of 1940 and Rule 206(4)-7 thereunder, and Section 13(d) of the Act and Rules 13d-1 and 13d-2 thereunder.
• These violations related to conflicts of interest disclosure and beneficial ownership reporting.
• Under the settlement, RTW Investments agreed to a cease-and-desist order, a censure, and a civil penalty of $1.4 million.

Stakeholder Impact

• Shareholders: The increased stake by a significant investor may be viewed positively, suggesting confidence, but the overall impact depends on the company's performance and future strategy.
• Creditors: No direct impact mentioned.
• Employees: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Customers: No direct impact mentioned.

Next Steps

• The Reporting Persons will continue to monitor the business and affairs of the Issuer.
• Future amendments to the Schedule 13D will be filed as required by SEC regulations.

Key Dates

Recommendation

The filing is an amendment to a Schedule 13D, primarily reporting a routine purchase of shares and an increase in beneficial ownership. It does not contain new strategic information, financial performance updates, or significant forward-looking guidance that would warrant a buy or sell recommendation. The existing holding and recent purchase suggest a 'hold' stance, reflecting continued but not aggressive interest.

Keywords

Orchestra Biomed Holdings, RTW Investments, Schedule 13D, Beneficial Ownership, Common Stock, Investment Advisor, Public Offering, SEC Filing